Outlook Therapeutics (OTLK) EBIT (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly EBIT of -$14.0 million for Q1 2026, down 13.2% year-over-year from -$16.2 million in Q1 2025, and down 4.03% quarter-over-quarter from -$13.5 million in Q4 2025.
Outlook Therapeutics (OTLK) EBIT (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported EBIT for 12 consecutive years, with -$14.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 13.2% year-over-year to -$14.0 million; the TTM figure through Mar 2026 stood at -$60.6 million (up 20.75% YoY), while the FY2025 annual figure was -$67.1 million, up 6.47% from the prior year.
- EBIT declined to -$14.0 million in Q1 2026 per OTLK's latest filing, from -$13.5 million in the prior quarter.
- Across five years, EBIT topped out at -$6.8 million in Q1 2023 and bottomed at -$22.9 million in Q3 2024.
- Historically, EBIT has averaged -$15.8 million across 5 years, with a median of -$15.7 million in 2025.
- Annual changes were most pronounced in 2023 — EBIT jumped 63.84% — and 2024, when it tumbled 176.98%.
- Outlook Therapeutics' EBIT stood at -$15.7 million in 2022, then soared by 34.2% to -$10.3 million in 2023, then plunged by 109.31% to -$21.6 million in 2024, then soared by 37.59% to -$13.5 million in 2025, then slipped by 4.03% to -$14.0 million in 2026.
- Business Quant data shows OTLK's EBIT at -$14.0 million in Q1 2026, -$13.5 million in Q4 2025, and -$17.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Outlook Therapeutics | 93.64 Mn | 82.40 Mn | -8,265.00 | -10.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.03 Mn |
| Dec 31, 2025 | -13.48 Mn |
| Sep 30, 2025 | -17.31 Mn |
| Jun 30, 2025 | -15.75 Mn |
| Mar 31, 2025 | -12.39 Mn |
| Dec 31, 2024 | -21.61 Mn |
| Sep 30, 2024 | -22.88 Mn |
| Jun 30, 2024 | -19.56 Mn |
| Mar 31, 2024 | -18.94 Mn |
| Dec 31, 2023 | -10.32 Mn |
| Sep 30, 2023 | -12.46 Mn |
| Jun 30, 2023 | -18.14 Mn |
| Mar 31, 2023 | -6.84 Mn |
| Dec 31, 2022 | -15.69 Mn |
| Sep 30, 2022 | -13.99 Mn |
| Jun 30, 2022 | -17.02 Mn |
| Mar 31, 2022 | -18.91 Mn |
| Dec 31, 2021 | -13.15 Mn |
| Sep 30, 2021 | -13.44 Mn |
| Jun 30, 2021 | -11.47 Mn |